A 15 months, double-Blind, randomized controlled trial comparing 18 weeks of two doses of Omalizumab to placebo to accelerate a symptom-driven Oral immunotherapy schedule in subjects aged 6 to 25 years with Multiple food allergies (BOOM).

一项为期 15 个月的双盲随机对照试验，比较了 18 周的两剂奥马珠单抗与安慰剂，以加速 6 至 25 岁多种食物过敏 (BOOM) 受试者的症状驱动口服免疫治疗计划。

• 批准号: 402372
• 负责人: Bgin Philippe
• 金额: $ 19.51万
• 依托单位: Centre hospitalier universitaire Sainte-Justine (Montral, Qubec)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-03-01 至 2022-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=402372&lang=en
• 关键词: Food Allergy; Omalizumab; Oral Immunotherapy

Oral immunotherapy (OIT) is a new treatment for food allergy, where allergists administer patients precisely measured amounts of their allergen to progressively deplete antibodies on allergy cells and build their tolerance over time up to a full portion o

口服免疫疗法（OIT）是一种治疗食物过敏的新方法，过敏症医生给患者精确测量其过敏原的量，以逐渐耗尽过敏细胞上的抗体，并随着时间的推移建立其耐受性，直至完全部分过敏。